Experience in the use of pharmacogenetic testing for personalizing warfarin dosing in outpatient conditions
Abstract
Background. The purpose of the study - evaluation of the effectiveness of using a personalized approach to the use of warfarin with pharmacogenetic testing. Methods. Open, prospective, non-randomized study of the efficacy of complex algorithm with indirect anticoagulants in patients with permanent atrial fibrillation in a clinic. Results. The correlation coefficient between the calculated and selected dose of warfarin was 0.93. That mean that, the predictive value of the selected algorithm for calculating the initial dose of warfarin was very high. Conclusions. implementation into the outpatient practice of complex algorithm of individual dose indirect anticoagulant warfarin, based on the results of pharmacogenetic testing Gage et al. algorithm contributes significantly increase to the quality of anticoagulation therapy, efficiency of individual dose of warfarin and increase the stability of the anticoagulant effect.
About the Authors
E. V. Gavrisyuk
Scientific Centre of expert evaluation of Medical Products
Russian Federation
Russian Federation
D. A. Sychev
Russian Medical Academy of Postgraduate Education I.M. Sechenov First Moscow State Medical University
Russian Federation
Russian Federation
R. E. Kazakov
Scientific Centre of expert evaluation of Medical Products
Russian Federation
Russian Federation
A. V. Kossovskaya
Scientific Centre of expert evaluation of Medical Products
Russian Federation
Russian Federation
V. F. Marinin
Scientific Centre of expert evaluation of Medical Products I.M. Sechenov First Moscow State Medical University
Russian Federation
Russian Federation
References
1. Антонов И.М., Аристов Е.Г., Сычев Д.А. [и др.] Антикоа-гулянтные клиники: зарубежный опят и перспективы для Российского здравоохранения // Креативная кардиология. 2010. № 1. С. 35-41.
2. Клиническая фармакогенетика / Сычев Д.А., Раменская Г.В., Игнатьев И.В., Кукес В.Г. М.: ГЭОТАР-Медиа, 2007. 50 с.
3. Conen D., Osswald S., Albert C. Epidemiology of atrium fibrillation. // Swiss Medical Weekly. 2009. Vol. 139. P. 346-352.
4. Ederhy S., Cohen A. Optimising stroke prevention in non-valvular atrial fibrillation // Expert Opin. Pharmacother. 2006. Vol. 7, No. 15. P. 2079-2094.
5. Epstein R.S., Moyer T.P., Aubert R.E. [et al.] Warfarin genotyping reduces hospitalization rates results from the MM-WES (Medco-Mayo Warfarin Effectiveness study) // J. Am. Coll. Cardiol. 2010. Vol. 55, No. 25. P. 2804-2812.
6. Fihn S.D., McDommel M., Matin D. [et al.] Risk factors for complications of chronic anticoagulation. A multicenter study. Warfarin Optimized Outpatient Follow-up Study Group // Ann. Intern. Med. 1993. Vol. 118. No. 7. P. 511-520.
7. Gage B.F., Eby C.S. Pharmacogenetics and anticoagulant therapy // J. Thromb. Thrombolysis. 2003. Vol. 16, No. 1-2. P. 73-78.
8. Hart R.G., Pearce L.A., Aguilar M.I. Meta-analysis antithrombotic therapy to prevent stroke in patient who have non-valvulal atrial fibrillation // Ann. Intern. Med. 2007. Vol. 146. P. 857-867.
9. Hylek E.M., Chang Y., Jensvold N. [et al.] Effect of intensity of oral anticoagulation on stroke severity and mortality in atrial fibrillation // N. Eng. J. Med. 2003. Vol. 349. P. 1019-1026.
10. Radaelli F., Paggi S., Terruzzi V [et al.] Management of warfarin associated coagulopathy in patients with acute gastrointestinal bleeding: A cross-sectional physician survey of current practice // Ann. Parmacoter. 2010. Vol. 44, No. 7-8. P. 1152-1157.
11. Winans A.R., Rudd K.M., Triller D. Assessing anticoagulation knowledge in patients new to warfarin therapy // Ann. Parmacother. 2010. Vol. 44, No. 7-8. P. 1152-1157.
Review
For citations:
Gavrisyuk E.V., Sychev D.A., Kazakov R.E., Kossovskaya A.V., Marinin V.F. Experience in the use of pharmacogenetic testing for personalizing warfarin dosing in outpatient conditions. Pacific Medical Journal. 2015;(1):60-62. (In Russ.)
Views:
258
Email this article 